Similar to the screen for Snail+ prostate cancer the follow-up screen for therapeutic vulnerabilities in enzalutamide-resistant CS2 cells pinpointed targets and pathways known to be involved in prostate cancer and hormone therapy resistance, including histone deacetylases, the PI3K/mTOR pathway, JAK-STAT signaling, DNA-PK, and Syk. This evidence concerns the gene PRKDC and prostate carcinoma.